Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug according to the results from a phase 3 clinical trial.
from Top Health News -- ScienceDaily https://ift.tt/2Zjxsqe
Health, Fitness,Dite plan, health tips,athletic club,crunch fitness,fitness studio,lose weight,fitness world,mens health,aerobic,personal trainer,lifetime fitness,nutrition,workout,fitness first,weight loss,how to lose weight,exercise,24 hour fitness,
Labels
Technology
New Post
[recent][newsticker]
MKRdezign
Powered by Blogger.
Post a Comment